CPT 0011U: Cordant CORE™ Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

CPT code 0011U is a Proprietary Laboratory Analyses (PLA) code that identifies Cordant CORE™ by Cordant Health Solutions, a laboratory-developed assay that tests oral fluid for drugs and applies an algorithmic analysis to estimate whether detected drug levels align with an estimated steady–state range. PLA codes are specific to a single manufacturer or laboratory test, making 0011U important for claims processing, coverage determinations, and lab billing consistency across payers. Nationally, algorithm-driven toxicology assays raise issues around clinical validity, coding specificity, and payer coverage policies.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find: an explanation of what the code represents and its clinical context; payer coverage considerations and where policy review may be required; benchmarking concepts relevant to proprietary lab tests; and operational details for billing and site-of-service expectations. The publication highlights how 0011U fits into laboratory service lines and the implications of PLA coding for utilization management, prior authorization workflows, and lab-to-payer communication.

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

Billing Code Overview

CPT code 0011U is a Proprietary Laboratory Analyses (PLA) code describing Cordant CORE™ by Cordant Health Solutions, a laboratory-developed drug test performed on an oral fluid specimen. The test combines laboratory measurement of drug(s) in oral fluid with an algorithmic analysis using patient data and the lab results to report a comparison of detected drug(s) to an estimated steady–state range.

Service type: Laboratory — Proprietary/Algorithmic Drug Test

Typical site of service: Clinical laboratory or reference lab

Clinical Context

A patient enrolled in an outpatient pain management program presents for routine monitoring of prescribed opioid therapy. The clinician orders 0011U (Cordant CORE™) to assess steady‑state exposure to a prescribed opioid using an oral fluid specimen combined with an algorithmic analysis that incorporates the assay result plus patient medication information and dosing history. The workflow includes: collection of an oral fluid sample at the clinic or collection site, shipment to the performing laboratory, laboratory immunoassay and/or mass spectrometry confirmation as needed, algorithmic analysis comparing measured drug concentrations to estimated steady‑state ranges based on the patient’s reported regimen, and a results report returned to the ordering provider indicating whether detected levels are consistent with expected steady‑state exposure.

Typical sites of service include outpatient clinics, pain management centers, addiction medicine clinics, behavioral health clinics, and independent collection sites that coordinate with the laboratory. Indications for testing include monitoring adherence, assessing unexpected toxicology results, evaluating suspected diversion or misuse, and periodic safety checks during chronic controlled‑substance therapy. The specimen type is oral fluid and the laboratory provides an interpreted comparison to steady‑state ranges rather than only a qualitative result.

Coding Specifications

Modifier	Description	When to Use
`00`

Taxonomy Code	Specialty	Notes
208100000X	Pain Medicine	Common ordering specialty for opioid steady‑state monitoring.
208000000X	Psychiatry & Neurology	Behavioral health and addiction medicine providers order monitoring tests.
207P00000X	Emergency Medicine	ED clinicians may order when evaluating intoxication or overdose.
261QP2300X	Clinical Laboratory	Performing laboratory specialty responsible for assay and algorithmic analysis.
207L00000X	Internal Medicine	Primary care physicians managing chronic opioid therapy may order this test.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`Z79.891`	Long term (current) use of opiate analgesic	Documents chronic opioid therapy when steady‑state testing is performed.
`F11.20`	Opioid dependence, uncomplicated	Relevant for monitoring adherence and potential misuse in opioid use disorder.
`F11.10`	Opioid abuse, uncomplicated	Used when assessing possible nonmedical opioid use or monitoring in substance use disorder care.
`R79.9`	Abnormal finding of laboratory study, unspecified	Used when ordering an interpretive lab test to evaluate abnormal drug level findings.
`Z51.89`	Encounter for other specified aftercare	May be used for ongoing monitoring visits in pain or addiction programs.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81025`	Urinalysis; qualitative or semiquantitative, multiple reagent strips, with microscopy	Often performed alongside oral fluid testing when urine drug testing is also used for monitoring.
`80307`	Drug screen, presumptive, any number of drug classes by instrumented chemistry analyzers (e.g., immunoassay), each procedure	May be used for initial presumptive screening of many drugs in urine; complements a PLA oral fluid test.
`80306`	Drug screen, presumptive, any number of drug classes by instrumented chemistry analyzers (e.g., immunoassay), definitive drug class testing not otherwise specified	Alternative screening code for presumptive testing in toxicology workflows.
`80305`	Drug test(s), presumptive, any number of drug classes by automated immunoassay technique	Another commonly billed presumptive screen code used in conjunction with definitive testing.
`80320`	Drug confirmation, each specimen, each drug class by definitive method (e.g., chromatographic, mass spectrometry)	Used when confirmatory testing by mass spectrometry is required following a presumptive or PLA result.

OpenPayer

Summary & Overview